For patients with disabilities following a stroke, gene therapy utilizing AAV carrying Sbno1 can upregulate the expression of Sbno1 in human hippocampal NSCs, thereby promoting the proliferation of endogenous NSCs and intrinsic repair. Here, SBNO1 is linked to stroke disorder.